AU2001286514A1 - Diagnosis and treatment of tumor-suppressor associated disorders - Google Patents

Diagnosis and treatment of tumor-suppressor associated disorders

Info

Publication number
AU2001286514A1
AU2001286514A1 AU2001286514A AU8651401A AU2001286514A1 AU 2001286514 A1 AU2001286514 A1 AU 2001286514A1 AU 2001286514 A AU2001286514 A AU 2001286514A AU 8651401 A AU8651401 A AU 8651401A AU 2001286514 A1 AU2001286514 A1 AU 2001286514A1
Authority
AU
Australia
Prior art keywords
tslc1
expression
disorder
proliferating
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286514A
Other languages
English (en)
Inventor
Yoshinori Murakami
Roger Harper Reeves
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Research Institute
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2001286514A1 publication Critical patent/AU2001286514A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
AU2001286514A 2000-08-15 2001-08-15 Diagnosis and treatment of tumor-suppressor associated disorders Abandoned AU2001286514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22526400P 2000-08-15 2000-08-15
US60225264 2000-08-15
PCT/US2001/025690 WO2002014557A1 (fr) 2000-08-15 2001-08-15 Diagnostic et traitement des troubles associes aux suppresseurs de tumeur

Publications (1)

Publication Number Publication Date
AU2001286514A1 true AU2001286514A1 (en) 2002-02-25

Family

ID=22844210

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286514A Abandoned AU2001286514A1 (en) 2000-08-15 2001-08-15 Diagnosis and treatment of tumor-suppressor associated disorders

Country Status (7)

Country Link
US (3) US6596493B1 (fr)
EP (1) EP1339871B1 (fr)
AT (1) ATE411037T1 (fr)
AU (1) AU2001286514A1 (fr)
CA (1) CA2419529C (fr)
DE (1) DE60136212D1 (fr)
WO (1) WO2002014557A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014557A1 (fr) * 2000-08-15 2002-02-21 The Johns Hopkins University School Of Medecine Diagnostic et traitement des troubles associes aux suppresseurs de tumeur
ATE382099T1 (de) * 2003-03-31 2008-01-15 Stichting Res Fonds Pathologie Nachweis von invasivem krebs induziert von hpv und dessen vorläufer läsionen mit invasionspotential
JP2007500132A (ja) * 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法
JP4942644B2 (ja) * 2005-02-28 2012-05-30 株式会社抗体研究所 抗ＩｇＳＦ４抗体及びその利用
ES2625259T3 (es) * 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
CN101153336B (zh) * 2006-09-27 2011-09-07 香港中文大学 检测dna甲基化程度的方法和试剂盒
US9102948B2 (en) 2006-11-17 2015-08-11 22Nd Century Limited, Llc Regulating alkaloids
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
US20110159499A1 (en) * 2009-11-25 2011-06-30 Quantalife, Inc. Methods and compositions for detecting genetic material
KR101769160B1 (ko) 2009-03-05 2017-08-17 옥스포드 바이오테라퓨틱스 리미티드 Ｃａｄｍ１에 특이적인 완전 인간 항체
EP3940084A1 (fr) 2011-02-09 2022-01-19 Bio-Rad Laboratories, Inc. Analyse d'acides nucléiques
WO2013163428A1 (fr) * 2012-04-25 2013-10-31 The Regents Of The University Of Colorado Détection de fusions de ret dans le cancer
JP7190165B2 (ja) * 2018-04-13 2022-12-15 学校法人近畿大学 慢性腎臓病罹患の可能性の判定のための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552277A (en) 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
WO1998056952A1 (fr) 1997-06-09 1998-12-17 University Of Southern California Methode de diagnostic du cancer basee sur des differences de methylation d'adn
DE69942861D1 (de) * 1998-08-07 2010-11-25 Immunex Corp Ldcam genannte moleküle
EP1124850A4 (fr) * 1998-10-28 2005-10-19 Human Genome Sciences Inc 12 proteines humaines secretees
AU1618500A (en) * 1998-11-12 2000-05-29 Incyte Pharmaceuticals, Inc. Human cell surface receptor proteins
WO2002014557A1 (fr) * 2000-08-15 2002-02-21 The Johns Hopkins University School Of Medecine Diagnostic et traitement des troubles associes aux suppresseurs de tumeur

Also Published As

Publication number Publication date
EP1339871B1 (fr) 2008-10-15
US7833712B2 (en) 2010-11-16
US7153657B2 (en) 2006-12-26
CA2419529A1 (fr) 2002-02-21
EP1339871A4 (fr) 2005-08-17
DE60136212D1 (de) 2008-11-27
US20030165974A1 (en) 2003-09-04
US20070072224A1 (en) 2007-03-29
CA2419529C (fr) 2013-02-12
ATE411037T1 (de) 2008-10-15
WO2002014557A1 (fr) 2002-02-21
EP1339871A1 (fr) 2003-09-03
US6596493B1 (en) 2003-07-22

Similar Documents

Publication Publication Date Title
AU2001286514A1 (en) Diagnosis and treatment of tumor-suppressor associated disorders
Kriegl et al. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer
Ariosa et al. A perspective on the role of autophagy in cancer
Clere et al. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis
Della Corte et al. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
Shah et al. Targeting ribonucleotide reductase M2 and NF-κB activation with didox to circumvent tamoxifen resistance in breast cancer
Takata et al. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma
WO2011031474A3 (fr) Utilisation de metformine dans le traitement et la prévention du cancer
Maury et al. Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies
WO2005013800A3 (fr) Activite elevee du mecanisme hedgehog dans des tumeurs du systeme digestif, et methodes de traitement de tumeurs du systeme digestif presentant une activite elevee du mecanisme hedgehog
AU7921701A (en) Immunotherapy for chronic myelocytic leukemia
Matsunaga et al. Involvement of the aldo–keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms
NO970039D0 (no) Fremgangsmåte for inhibering av cancer matastaser ved oral administrering av opplöselig modifisert sitruspektin
WO1999046279A3 (fr) INHIBITEURS DE LA 17β-HYDROXYSTEROIDE DESHYDROGENASE DU TYPE 5 ET DU TYPE 3 ET METHODES D'UTILISATION ASSOCIEES
Megova et al. Isocitrate dehydrogenase 1 and 2 mutations in gliomas
WO2001042467A3 (fr) Genes, compositions, kits et techniques d'identification, d'evaluation, et de prevention du cancer du col de l'uterus et therapie
WO2007092414A8 (fr) Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
Gurova et al. Paradoxical role of apoptosis in tumor progression
Xia et al. The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
WO2006053201A3 (fr) Traitement du cancer par inhibition simultanee de b-raf et restauration ou mimetisme de l'activite de p16 ink4a
Pan et al. CD26/dipeptidyl peptidase IV and its multiple biological functions
Furukawa et al. PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation
Marcé et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy
WO2001007028A3 (fr) Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate